Creo Medical Group (LON:CREO) Shares Up 1.8% – Time to Buy?

Creo Medical Group PLC (LON:CREO) traded up 1.8% on Friday. The stock traded as high as GBX 12.47 and last traded at GBX 12.47. 126,580 shares changed hands during trading, a decline of 83% from the average daily volume of 748,931 shares. The stock had previously closed at GBX 12.25.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Stock Up 1.8%

The company has a current ratio of 3.22, a quick ratio of 2.19 and a debt-to-equity ratio of 8.20. The stock has a market cap of £60.57 million, a P/E ratio of 12.47 and a beta of 1.56. The company’s 50 day moving average price is GBX 12.84 and its two-hundred day moving average price is GBX 12.91.

Insider Activity at Creo Medical Group

In other Creo Medical Group news, insider Craig Jonathan Gulliford purchased 6,250 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average price of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees acquired 6,250 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, with a total value of £875. 7.00% of the stock is currently owned by company insiders.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.